|
|
Volumn 1, Issue 4, 2009, Pages 387-389
|
|
Probabilities of success for antibody therapeutics
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADALIMUMAB;
ALEMTUZUMAB;
ARZERRA;
ATLIZUMAB;
BASILIXIMAB;
BEVACIZUMAB;
CANAKINUMAB;
CERTOLIZUMAB PEGOL;
CETUXIMAB;
DACLIZUMAB;
DENOSUMAB;
ECULIZUMAB;
EFALIZUMAB;
GEMTUZUMAB OZOGAMICIN;
GOLIMUMAB;
IBRITUMOMAB TIUXETAN;
INFLIXIMAB;
MONOCLONAL ANTIBODY;
MOTAVIZUMAB;
NATALIZUMAB;
OFATUMUMAB;
OMALIZUMAB;
PALIVIZUMAB;
PANITUMUMAB;
RANIBIZUMAB;
RAXIBACUMAB;
RITUXIMAB;
SIMPONI;
STELARA;
TOSITUMOMAB I 131;
TRASTUZUMAB;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
USTEKINUMAB;
ACUTE GRANULOCYTIC LEUKEMIA;
AMINO ACID SEQUENCE;
ANKYLOSING SPONDYLITIS;
ANTHRAX;
ASTHMA;
BREAST CANCER;
CHRONIC LYMPHATIC LEUKEMIA;
CHRONIC MYELOID LEUKEMIA;
CLINICAL PRACTICE;
COLORECTAL CANCER;
CROHN DISEASE;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG SAFETY;
EDITORIAL;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
KIDNEY GRAFT REJECTION;
MUCKLE WELLS SYNDROME;
MULTIPLE SCLEROSIS;
NONHODGKIN LYMPHOMA;
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA;
PSORIASIS;
PSORIATIC ARTHRITIS;
RETINA MACULA DEGENERATION;
RHEUMATOID ARTHRITIS;
VIRUS INFECTION;
|
|
EID: 77953669043
PISSN: 19420862
EISSN: None
Source Type: Journal
DOI: 10.4161/mabs.1.4.9031 Document Type: Editorial |
|
Times cited : (12)
|
|
References (6)
|
